Cerebrolysin has been studied in people, especially in stroke and neurological settings, but results vary by condition and study. It is marketed in some regions, while broad cognitive-enhancement claims are not established.
Still uncertain: Use for cognitive enhancement in healthy people, consistent benefit across stroke populations, and equivalence of non-authenticated products are not established.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Porcine brain-derived mixture of low-molecular-weight peptides and amino acids
Multiple randomized trials and meta-analyses exist, but results differ by indication. Alzheimer trials show some short-term cognitive/global signals, whereas the 2023 Cochrane stroke review found no mortality benefit and a potential increase in non-fatal serious adverse events.
Regulatory status
Regulatory availability varies by country; it is not an FDA-approved cognitive enhancer. Jurisdiction-specific product status must be checked separately.
Main limitations
Use for cognitive enhancement in healthy people, consistent benefit across stroke populations, and equivalence of non-authenticated products are not established.
Safety
Safety conclusions differ by clinical setting; acute-stroke Cochrane data raise concern about non-fatal serious adverse events.
Evidence reviewed
2026-09-18
i
Multiple randomized trials and meta-analyses exist, but results differ by indication. Alzheimer trials show some short-term cognitive/global signals, whereas the 2023 Cochrane stroke review found no mortality benefit and a potential increase in non-fatal serious adverse events.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Short-term cognitive and global signals favoured Cerebrolysin; cognitive effect at 6 months was not statistically significant while global change remained significant.
Safety conclusions differ by clinical setting; acute-stroke Cochrane data raise concern about non-fatal serious adverse events.
Safety varies by population and indication. Cochrane stroke evidence found a possible increase in non-fatal serious adverse events despite little/no difference in total serious adverse events.
Technical details
Mechanism / biologyProposed neurotrophic and neuroprotective effects are attributed to a complex mixture of peptides/amino acids; no single active peptide explains the clinical product.
Route / formulation boundaryEvidence applies to a specific biologic mixture formulation, commonly administered intravenously in trials; generic 'peptide blends' are not equivalent.
Identity / data-quality noteTreat as a defined peptide/amino-acid mixture, not a single peptide.
Study / label regimen evidenceMultiple human trial regimens verified. Published studies commonly used 30 mL/day IV in specific Alzheimer, stroke and TBI protocols; these are study/product regimens, not healthy-person enhancement guidance.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
4structured study records
3outcome records
6linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
